(Q33382613)

26 July 2017

title

Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients (English)

1 reference

26 July 2017

1 reference

Vincenzo Mirone

9

0 references

Riccardo Autorino

3

object named as

Riccardo Autorino

1 reference

26 July 2017

6

Ciro Imbimbo

1 reference

26 July 2017

10

Sabino De Placido

1 reference

26 July 2017

5

Nicola Longo

1 reference

26 July 2017

Giuseppe Di Lorenzo

1

1 reference

26 July 2017

Vincenzo Montesarchio

2

1 reference

26 July 2017

Teresa Bellelli

4

1 reference

26 July 2017

Emilio Morelli

7

1 reference

26 July 2017

Gianluca Giannarini

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

115

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

517-523

1 reference

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Fluorouracil and recombinant human interferon alfa-2a in the treatment of metastatic chemotherapy-refractory urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Update on chemotherapy for advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24055

7 January 2021

Identifiers

DOI

10.1002/CNCR.24055

1 reference

26 July 2017

1 reference